biostudies-literatureUnknown6(4)Petrelli F<h4>Importance</h4>The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival. The Three or Six Colon Adjuvant (TOSCA) trial compared 3 months with 6 months of adjuvant fluoropyrimidine and oxaliplatin-based chemotherapy in patients with stage III colon cancer. The utility remains unknown.<h4>Objective</h4>To assess the noninferiority and toxic effects of 3 vs 6 months of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) adjunct chemotherapy among patients with high-risk stage II resected colorectal cancer enrolled in the TOSCA trial.<h4>Design, setting, and participants</h4>The TOSCA study was a nonJAMA oncology547-551https://www.ebi.ac.uk/biostudies/studies/S-EPMC7042800biostudies-literatureAssessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.PMC7042800Rulli EPetrelli FBanzi MCardellino GGLabianca RCorsi DLonardi SPusceddu VCinieri SZampino MGalli FCiuffreda LZaniboni AMattioli RMarchetti PRonzoni MSobrero AZagonel VMambrini AMaiello ERosati GCorallo SRimassa LfalseAssessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.<h4>Importance</h4>The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival. The Three or Six Colon Adjuvant (TOSCA) trial compared 3 months with 6 months of adjuvant fluoropyrimidine and oxaliplatin-based chemotherapy in patients with stage III colon cancer. The utility remains unknown.<h4>Objective</h4>To assess the noninferiority and toxic effects of 3 vs 6 months of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) adjunct chemotherapy among patients with high-risk stage II resected colorectal cancer enrolled in the TOSCA trial.<h4>Design, setting, and participants</h4>The TOSCA study was a non2020-01-01T00:00:00Z2020 Apr2025-05-18T13:36:03.353Z2025-05-18T13:36:03.353ZS-EPMC70428003205313310.1001/jamaoncol.2019.6486